shRNA-Mediated Suppression of γ-Synuclein Leading to Downregulation of p38/ERK/JNK Phosphorylation and Cell Cycle Arrest in Endometrial Cancer Cells

Sun, Dongsheng; Li, W.-Y.; Chen, S.-H.; Zhi, Zhe; Lin, Hui; Fan, Jiangtao; Fan, Yonggang

doi:10.1134/s0026893320060114

Cited by 4 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this tumor type, γS promotes cell survival and proliferation by AKT activation, playing a leading role in this pathogenesis [ 109 ]. Contrary to what we mentioned for αS, all the reports connecting γS with ERK or AKT pathways indicate that this family member promotes activation of these pathways including gastric [ 110 ], cervical [ 111 ], ovarian [ 112 ], and endometrial cancers [ 113 ]. Furthermore, in all the tumor types in which it was explored, γS downmodulates JNK, leading to increased survival and evading apoptosis.…”

Section: Synuclein-controlled Pathways In Cancercontrasting

confidence: 67%

“…During recent decades, several studies associated γS levels with poor outcome in endometrial adenocarcinoma [ 61 , 113 ], which correlates with a worse prognosis for uterine corpus endometrial carcinoma patients with high levels of SNCG transcripts ( Figure 4 ). It has also been proposed that γS could be a prognostic marker for tumor cell migration in biliary carcinomas [ 120 ].…”

Section: Synucleins As Cancer Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Synuclein Proteins in Cancer Development and Progression

Zanotti,

Malizia,

Cesatti Laluce

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Synucleins are a family of small, soluble proteins mainly expressed in neural tissue and in certain tumors. Since their discovery, tens of thousands of scientific reports have been published about this family of proteins as they are associated with severe human diseases. Although the physiological function of these proteins is still elusive, their relationship with neurodegeneration and cancer has been clearly described over the years. In this review, we summarize data connecting synucleins and cancer, going from the structural description of these molecules to their involvement in tumor-related processes, and discuss the putative use of these proteins as cancer molecular biomarkers.

show abstract

Section: Synuclein-controlled Pathways In Cancercontrasting

confidence: 67%

Section: Synucleins As Cancer Biomarkersmentioning

confidence: 99%

Synuclein Proteins in Cancer Development and Progression

Zanotti,

Malizia,

Cesatti Laluce

et al. 2023

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Overexpression of SNCG has been reported in a variety of malignant solid tumors, including ovarian and colorectal cancer [15,16], and is especially overexpressed in advanced tumors, suggesting that SNCG has lost its original tissue specificity during carcinogenesis. Increased SNCG expression levels in primary tumors have been positively correlated with distant metastasis or tumor recurrence in breast, colon and pancreatic cancer patients, and are associated with poor prognosis in many human cancers [17][18][19]. We have previous reported that SNCG is highly expressed in the saliva, serum, and tissues of OSCC patients and proposed that SNCG could be a potential novel diagnostic marker for OSCC [20,21].…”

Section: Discussionmentioning

confidence: 99%

γ-Synuclein promotes proliferation and inhibits apoptosis of oral squamous cell carcinoma via JAK2/STAT5b signaling pathway

Yang

2024

Am J Cancer Res

View full text Add to dashboard Cite

γ-Synuclein (SNCG) has various biological functions associated with tumorigenesis. However, the role of SNCG in oral squamous cell carcinoma (OSCC) remains unknown. In this study, we found that SNCG expression is associated with the malignancy of OSCC. We showed that SNCG promotes cell proliferation and inhibits apoptosis in OSCC. Mechanistically, we demonstrated for the first time, that SNCG interacts with ERK1/2 and promotes its phosphorylation leading to activation of the JAK2/STAT5b signaling pathway. Subsequent experiments with STAT5b interference and ERK1/2 inhibitor treatment reversed the effects of SNCG on OSCC cell proliferation, apoptosis and cell cycle progression. Our findings suggest that SNCG functions as an oncogene in OSCC by targeting the JAK2/ STAT5b axis and thus may be a potential new prognostic marker and therapeutic target in OSCC.

show abstract

“…Thus, improving early diagnosis of PD ( Xhima et al, 2018 ). shRNA also has the potential to suppress γ-synuclein which can be explored as a novel approach ( Sun et al, 2020 ). The next major concern about siRNAs is due to miRNA-like effects their off-target effects leading to unintended gene silencing of up to 1,000 gene transcripts.…”

Section: Challenges For Nucleic Acid-based Therapeuticsmentioning

confidence: 99%

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease

Suvarna

Deshmukh²,

Murahari³

2022

Front. Pharmacol.

View full text Add to dashboard Cite

α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease.

show abstract

shRNA-Mediated Suppression of γ-Synuclein Leading to Downregulation of p38/ERK/JNK Phosphorylation and Cell Cycle Arrest in Endometrial Cancer Cells

Cited by 4 publications

References 26 publications

Synuclein Proteins in Cancer Development and Progression

Synuclein Proteins in Cancer Development and Progression

γ-Synuclein promotes proliferation and inhibits apoptosis of oral squamous cell carcinoma via JAK2/STAT5b signaling pathway

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease

Contact Info

Product

Resources

About